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cancer survivors are affected by multiple therapy-re-
lated sequelae. A comprehensive network of late effects 
clinics should be established to ensure specialized and 
risk-adapted care for every childhood cancer survivor in 
Germany.
© 2018 S. Karger GmbH, Freiburg
Introduction
As survival rates of pediatric cancer patients improved signifi-
cantly over the last decades, the number of childhood cancer survi-
vors is growing worldwide [1]. However, several studies demon-
strated that these patients face a reduced life expectancy compared 
to sex- and age-adjusted peers [2]. Moreover, they can be affected 
by multiple therapy-related sequelae, determined by different fac-
tors such as initial cancer diagnosis, treatment, sex and age. These 
late effects mainly consist of endocrine, cardiac, renal and pulmo-
nary conditions as well as secondary malignancies. Radiotherapy 
constitutes an important risk factor for the development of endo-
crine disruptions as well as secondary neoplasms necessitating 
early diagnosis and treatment to prevent late deaths [3, 4]. Thirty 
years after cancer diagnosis, although still in early adulthood, 
about 70% of cancer survivors struggle with at least 1 chronic con-
dition [5].
With the knowledge of late effects, the need for late effects clin-
ics for adult childhood cancer survivors was expressed. Their aim 
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Summary
Background: Childhood cancer survivors are at risk for 
therapy-related sequelae and, therefore, require long-
term follow-up. At 2 university hospitals in Germany 
collaborative multidisciplinary late effects clinics were 
installed to provide specialized care and to evaluate the 
current health status of these patients in a clinical set-
ting. Patients and Methods: Every patient who visited 
the late effects clinics at the university hospital in 
Lübeck and Erlangen over a period of 3 years and met 
the inclusion criteria was included in the study. Pa-
tients’ characteristics as well as cancer diagnosis, treat-
ment related factors and the prevalence of chronic 
health conditions were assessed. Results: 220 patients 
attended the late effects clinics during the observation 
period. The median follow-up period was 16 years 
(range 5–45 years). In total over 64% of the patients 
were affected by at least 1 chronic health condition, in-
cluding endocrine disruptions in 19.1% of the patients. 
Moreover, secondary neoplasms occurred in 9.1% of 
the study participants. Conclusion: German childhood 
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should be to offer specialized care as well as routine follow-up in-
vestigations to ensure early diagnosis and treatment of possible 
cancer-therapy-related problems [6–8]. Based on treatment- and 
patient-related factors, standard surveillance is supposed to be 
modified and adapted individually attempting to create a personal 
risk-adapted surveillance program for each survivor. National and 
international guidelines recommending risk-adapted surveillance 
have been developed in the last decade to optimize and standardize 
long-term follow-up (LTFU) [9, 10].
Current estimations assume there are more than 25,000 adult 
former childhood cancer survivors more than 5 years after end of 
therapy in Germany (P. Kaatsch, personal communication, June 
28th, 2017). Several mainly questionnaire-based surveys revealed an 
elevated risk for late effects in this cohort, although clinical data is 
still lacking [11, 12]. However, there are only a few late effects clin-
ics in Germany and these have not yet created a comprehensive 
network to offer localized and structured care.
Therefore, late effect clinics at 2 German university hospitals 
(Lübeck and Erlangen) covering the upper North as well as the 
Southeast of Germany were established to illuminate the current 
health status of German childhood cancer survivors as well as their 
need for specialized routine care. To the best of our knowledge the 
present study is the first to characterize this currently insufficiently 
attended population based on clinical data. Moreover, it illustrates 
a possible structure of multidisciplinary late effects clinics at differ-
ent locations as a basis for a collaborative network.
Patients and Methods
All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national re-
search committee and with the 1964 Helsinki declaration and its amendments. 
The study protocol was specifically approved by the ethical review boards of the 
Universities of Lübeck and Erlangen. Informed consent was obtained from all 
individual participants included in the study.
Potential study participants were seen in 2 separate late effects clinics at 2 
university hospital centers in Germany – at the university hospital Schleswig-
Holstein in Lübeck and the university hospital Erlangen in Bavaria. In 2014 
both institutions established outpatient clinics for a yearly long-term follow-up 
of childhood cancer survivors. Potential patients and study participants were 
informed about these clinics via 3 different approaches. First, every patient that 
turned 18 during the study period was routinely transferred from the local de-
partments of Pediatric Hematology and Oncology to the late effects clinics in a 
structured transition process. Second, all former patients from Lübeck and Er-
langen, who were treated at the local departments of Pediatric Hematology and 
Oncology and were already adults, were contacted via mail to inform them 
about the initiation of these clinics. Furthermore, the late effects clinics were 
presented on the clinic homepages to enable additional patients, who had not 
already been approached, to attend the clinics.
For this report, we restricted our analysis to patients visiting the late effects 
clinics between March 2014 and February 2017 (Lübeck) and January 2014 and 
December 2016 (Erlangen), respectively, and met the inclusion criteria (fig. 1).
Former medulloblastoma patients that were >18 years, when first diagnosed 
with cancer, were included in the analysis, as these patients were treated in De-
partments of Pediatric Hematology and Oncology according to German Pediat-
ric Oncologic Clinical Trials.
The patients were examined by a pediatric oncologist in both centers as 
well as by an endocrinologist (Lübeck) and a medical oncologist (Erlangen), 
respectively. This included a physical examination and a basic laboratory 
workup with a complete blood count, serum electrolytes and an assessment of 
liver and kidney function. Based on their risk of developing late effects, the 
patients underwent additional examinations, such as lung function tests, echo-
cardiographies or magnetic resonance imaging and had consultations with 
specialists e.g. dermatologists, orthopedists or human geneticists. The underly-
ing risk stratifications were performed according to existing guidelines and 
recommendations [9, 10, 13–16]. Chronic health conditions were diagnosed by 
specialists of the corresponding discipline based on standard diagnostic ap-
proaches for the general population (e.g. diagnosis of hearing loss in case of a 
pathologic audiogram; diagnosis of cardiomyopathy in case of a pathologic 
echocardiography). Patients at the late effects clinic in Lübeck were also seen 
by a social worker for a socioeconomic consultation. Most patients attended 
the late effects clinics several times but for this report we only collected data 
from the latest physician’s documentation of the medical history and the phys-
ical examination.
Statistical Analysis
Data on quantitative characteristics are expressed as median and range. 
Data on qualitative characteristics are expressed as percent values or absolute 
numbers as indicated. Comparisons between 2 groups were calculated using 
Fisher’s exact test, for comparisons between more than 2 groups we employed 
the chi-square test. A value of p <0.05 was considered statistically significant. 
Comparative curve analysis was performed employing the Mantel-Cox test. All 
statistical analyses were performed using IBM SPSS Statistics 22.0 and Graph-
Pad Prism 6.0.
Fig. 1. Study flow chart.
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Results
Patient Characteristics
Of the 220 patients eligible for this analysis, 112 (50.9%) were 
treated in Lübeck and 108 (49.1%) in Erlangen. A total of 108 pa-
tients were transferred to the clinics through a structured transi-
tion process from the local departments of Pediatric Hematology 
and Oncology during the study period. As 8 of these patients did 
not meet the inclusion criteria for the present study, 100 patients 
(92.6%) of this cohort were included constituting almost half 
(45.5%) of the study participants. Furthermore, 80 (36.4%) patients 
that were contacted via mail followed the invitation for a long-term 
follow-up. As a total of 472 former patients were approached via 
mail, this corresponds to a response rate of 17%. An additional 40 
(18.2%) patients found information about the new institutions on-
line and thus decided to attend the clinics.
Of the patients seen in Lübeck, 84 patients (75% of all patients 
in Lübeck) were originally treated at the local Department of Pedi-
atric Hematology and Oncology, 96 (88.9% of all patients in Erlan-
gen) in Erlangen. The patients attended the late effects clinic a 
mean of 1.72 times during the study period (range 1–8 times). 
About half of the patients (103, 47.8%) visited the clinics twice or 
more often. For a more detailed overview of patients’ characteris-
tics see table 1.
Chronic Health Conditions
In this study, 141 patients (64.1%) suffered from at least 1 
chronic health condition (range 1–15 chronic health conditions). 
Out of these, 54 patients (24.5%) were affected by 1 chronic health 
condition, 22 patients (10%) by 2 and 65 patients (29.6%) were di-
agnosed with 3 or more health impairments. Types and distribu-
tion of chronic health conditions are summarized in table 2.
Endocrine Disruptions and Fertility Issues
Among all documented health conditions, most patients suf-
fered from endocrine disruptions (19.1%). Hypothyroidism was 
the most frequent endocrine dysfunction affecting 36 patients 
(16.4%). It was diagnosed more often in women (22, 19.6% of all 
female participants) than in men (14, 6.8% of all male participants). 
Out of all irradiated patients, 28 patients (28.3%) developed hypo-
thyroidism after any type of radiotherapy, 15 patients (41.7%) after 
neck or chest irradiation. In comparison, only 21 of 182 patients 
(11.5%) without any neck or chest irradiation suffered from the 
same condition (p <0.001). Furthermore, a trend towards a correla-
tion between radiation dose and hypothyroidism (p = 0.222) could 
be demonstrated (fig. 2). We have not seen any significant correla-
tion between primary cancer diagnosis, sex or patients’ origin and 
the development of hypothyroidism in later life.
Table 1. Patients’ characteristics (n = 220)
Characteristic Years
Age at cancer diagnosis
Median  8.5
Range  0–27
Age at last follow-up
Median 24
Range 18–57
Time since diagnosis
Median 16
Range  5–45
n (%)
Sex
Female 112 (50.9)
Male 108 (49.1)
Primary cancer diagnosis
Leukemia  79 (35.9)
Lymphoma  46 (20.9)
Intracranial malignancy  29 (13.2)
Sarcoma  27 (12.3)
Renal tumor  13 (5.9)
Germ cell tumor   8 (3.6)
Neuroblastoma   5 (2.3)
Othera  13 (5.9)
Cancer treatment
No chemotherapy, no radiotherapy  15 (6.8)
Chemotherapy 205 (93.2)
Radiotherapy
Any irradiation  99 (45.0)
Cranial irradiation  67 (30.5)
Neck or chest irradiation  38 (17.3)
Abdominal or pelvic irradiation  24 (10.9)
Total body irradiation  10 (4.5)
Combined radiochemotherapy  96 (43.6)
aMyelodysplastic syndrome, retinoblastoma, thyroid carcinoma, hepatocellular 
carcinoma, histiocytosis, inflammatory myofriboblastic tumour, papillary 
 cystadenofibroma, lipoblastoma and a ganglioneuroma.
Health condition Patients, n (%)
Overall 141 (64.1)
Endocrine disruptions  42 (19.1)
Fertility issues  38 (17.3)
Neurologic impairment  37 (16.8)
Metabolic changes  35 (15.9)
Psychiatric disorders  33 (15.0)
Benign tumors (extracranial)  26 (11.8)
Orthopaedic complaints  24 (10.9)
Cardiac diseases  19 (8.6)
ENT dysfunctions  19 (8.6)
Gastrointestinal diseases  18 (8.2)
Pulmonary diseases  16 (7.3)
Hematological disorders  13 (5.9)
Ophthalmologic diseases  13 (5.9)
Nephropathy  12 (5.5)
Bone health impairmenta  10 (4.5)
Dermatological diseases   8 (3.6)
Hypogammaglobulinemia   5 (2.3)
Chronic graft-vs-host-disease   4 (1.8)
aExcluding patients with a singular vitamin D defi-
ciency.
Table 2. Non-malig-
nant chronic health 
conditions
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Eight patients (3.6%) were diagnosed with growth hormone de-
ficiencies. 4 patients (1.8%) were affected by hyperparathyroidism. 
3 out of these 4 patients (75%) received cranial or mediastinal 
irradiation.
Fertility problems occurred in 38 patients (17.3%) mostly asso-
ciated with hypogonadism in 15 patients (6.8%). Low serum anti-
Mullerian hormone (AMH) affected 10 patients (8.9% of all female 
patients). It was only routinely assessed at 1 study site (Lübeck). 
Therefore 9 out of these 10 affected female patients were diagnosed 
at this center (15.5% of females treated in Lübeck). Erectile dys-
function occurred in 2 patients (1.9% of all male patients). Further-
more, 14 patients (6.4%) were affected by additional fertility prob-
lems including hysterectomy and oophorectomy. Supplemental 
table  1 summarizes the detailed analysis of all endocrine deficits 
(www.karger.com/?DOI=488203).
Subsequent Neoplasms
Overall, 39 subsequent neoplasms occurred in 20 patients 
(9.1%). 9 Patients developed 1 additional neoplasm, 6 were affected 
by 2 subsequent neoplasms, 3 by 3 and 1 patient each by 4 or 5, re-
spectively. This analysis excluded late relapses as well as extracra-
nial benign tumors. All patients with 3 or more subsequent neo-
plasms were female.
The median interval between the first oncologic diagnosis and 
the diagnosis of the first subsequent neoplasm was 15 years (range: 
8–42 years). Median intervals for further subsequent neoplasms 
were longer with 21 years (range: 13–40 years) for the second, 22 
years (range: 15–28 years) for the third, 29.5 years for the fourth 
(range: 29–30) and 31 years for the fifth subsequent neoplasm. Fig-
ure 3 illustrates the increasing cumulative incidence for the most 
frequent subsequent neoplasms, basal cell carcinoma (BCC) and 
meningioma, emerging with increasing time after primary cancer 
diagnosis. BCCs occurred significantly earlier than meningiomas 
(p = 0.016).
All subsequent neoplasms but 1 occurred in previously irradi-
ated areas (p <0.001). Intracranial tumors only occurred after cra-
nial irradiation. Some of the entities occurred more than once in 1 
patient and were diagnosed as independent neoplasm events rather 
than relapses by histopathologic examination. For a more detailed 
overview of patients’ characteristics see table 3.
Additional Chronic Health Conditions 
Neurologic impairment including epileptic seizures, strokes, 
mental and/or motoric retardation, was documented in 37 patients 
(16.8%). Psychiatric disorders were diagnosed in 33 patients (15%).
Metabolic changes were detected in 35 patients (15.9%) includ-
ing hypercholesterolemia in 14 patients (6.4%), obesity in 14 pa-
tients (6.4%), dyslipidemia in 3 patients (1.4%), diabetes mellitus 
type 1 in 3 patients (1.4%) and diabetes mellitus type 2 in 2 patients 
(0.9%). 
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Fig. 3. Occurrence of basal cell carcinomas and 
meningiomas after initial cancer diagnosis.
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Fig. 2. Correlation between radiotherapy and 
 hypothyroidism. a) Hypothyroidism in patients 
treated with or without radiotherapy; b) Hypo-
thyroidism in patients after cervicothoracic irradia-
tion, subdivided according to the applied radiation 
doses.
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Benign extracranial tumors occurred in 26 patients (11.8%), in-
cluding uterine myoma, fibroadenomas of the breast, neurinomas, 
focal nodular hyperplasias of the liver and lipomas. Thyroid adeno-
mas affected 11 patients (5%). Of these 9 patients (81.8%) received 
cervical and/or thoracic irradiation.
Orthopedic complaints affected 24 patients (10.9%). Ten pa-
tients (4.5%) were affected by bone health impairment, including 6 
patients (2.7%) with osteonecrosis and 2 patients (0.9%) with oste-
oporosis. Additionally, vitamin D deficiency was diagnosed in 34 
patients (15.5%).
Cardiovascular diseases affected 19 patients (8.6%). More than 
half of these patients (10 patients, 4.5%) suffered from arterial hy-
pertension. Cardiomyopathies occurred in 6 patients (2.7%) in-
cluding 1 patient (0.5%) after heart transplantation due to conges-
tive heart failure.
Lung diseases were documented in 16 patients (7.3%). Obstruc-
tive lung disease constituted the most frequent finding (10 patients, 
4.5%).
Additionally, ear, nose and throat dysfunctions occurred in 19 
patients (8.6%), including high frequency hearing loss in 13 pa-
tients (5.9%).
One patient (0.5%) died due to multiple subsequent chronic 
health conditions and second neoplasms during the time the study 
was conducted. Table  2 summarizes all non-malignant chronic 
health conditions.
Discussion
Optimal care and structured risk-adapted surveillance for long-
term childhood cancer survivors is still subject of research and on-
going development. Several models of care for LTFU of these pa-
tients have been proposed including shared care LTFU programs 
as a collaboration between general practitioners (GPs) and cancer 
centers, GP-led models as well as clinic-based models of LTFU by a 
multidisciplinary team [6, 17–19]. Patients’ satisfaction with LTFU 
was mostly dependent on coordination and communication be-
tween the involved specialists as well as their expertise concerning 
late effects and LTFU [18, 20]. As the management of therapy-re-
lated chronic health conditions often requires multidisciplinary 
cooperation, we favored a clinic-based model of LTFU [19]. A 
team of clinic physicians cooperates closely in order to facilitate 
risk-adapted surveillance at a single institution including all re-
quired specialist’s consultations in 1 day [21, 22]. GPs were in-
cluded in the LTFU process as they conduct follow-up examina-
tions that do not require specialists’ consultation.
After 3 years a first evaluation of 220 patient characteristics and 
health status was performed to verify the prevalence of late effects 
in clinical examinations by a multidisciplinary team in German 
cancer survivors that has to date only been assessed in question-
naire-based surveys. 
Over 64% of the study participants were diagnosed with chronic 
health impairment a median of 16 years after childhood cancer di-
agnosis, revealing a high number of German childhood cancer sur-
vivors struggling with possible therapy-related sequelae. However, 
the prevalence of chronic diseases in the present study was lower 
than in the North American St. Jude Lifetime Cohort Study, which 
might be due to the fact that median age and time passed since can-
cer treatment were significantly lower in our cohort [16].
Endocrine disruptions affected a fifth of the study participants 
and were the most common chronic health condition in the study 
population. This is in keeping with previously published data, 
demonstrating that endocrine late effects constitute one of the 
most frequent sequelae [23, 24]. Almost every fifth female child-
hood cancer survivor was affected by hypothyroidism, which ren-
ders the disorder significantly more common in our study group 
than in age-adjusted controls from general population [25]. Fur-
thermore, cervical and thoracic irradiation could be demonstrated 
as major risk factors for the development of hypothyroidism. Al-
though the absolute number of irradiated patients with subsequent 
hypothyroidism was low, a dose-dependent correlation, as postu-
lated in previous papers, could be observed [26].
Further endocrine deficits were documented illustrating the 
complexity of possible late effects that must be considered in a clin-
ical setting. Interestingly, primary hyperparathyroidism, a rather 
rare disease in the general population, was diagnosed in almost 2% 
of the study participants [27]. The majority of the affected patients 
was exposed to therapeutic irradiation emphasizing a previously 
discussed link [28].
Moreover, approximately 17% of our patients reported fertility 
issues. About half of these patients were affected by primary or sec-
ondary hypogonadism constituting a frequent sequela after cranial 
or pelvic irradiation and/or chemotherapy. The relevance of low 
serum AMH in the early detection of premature ovarian insuffi-
ciency has been controversially discussed [15, 29]. However, its 
role as a screening tool is more widely accepted and may be helpful 
in a multidisciplinary setting to decide which patient should be 
transferred to the associated fertility clinic. The lower overall prev-
alence of premature ovarian insufficiency in our cohort compared 
Table 3. Subsequent neoplasms
Entity Patients, n (%) Diagnoses, n
Basal cell carcinomas 9 (4.1) 14
Meningiomas 3 (1.4)  6
Cavernomas 3 (1.4)  4
Thyroid cancer 3 (1.4)  3
Breast cancer 2 (0.9)  3a
Melanoma 1 (0.5)  1
Lentigo maligna 1 (0.5)  1
Renal cell carcinoma 1 (0.5)  1
Gastric cancer 1 (0.5)  1
Leukemia 1 (0.5)  1
Osteosarcoma 1 (0.5)  1
Prolactinoma 1 (0.5)  1
Acoustic neurinoma 1 (0.5)  1
Trigeminal neurinoma 1 (0.5)  1
aOne patient was affected by bilateral breast cancer.
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to previously published data, revealing a prevalence over 10% at a 
median age of 31.7 years, may be due to the younger median age of 
24 years in our study group [30].
The development of a subsequent neoplasm is one of the most 
life-threatening late effects after childhood cancer and constitutes 
an especially troubling worry for cancer survivors [31]. Radiother-
apy has been demonstrated to be a major risk factor [3]. In our co-
hort 9% of patients developed subsequent neoplasms occurring al-
most exclusively in irradiated patients. BCCs as well as thyroid and 
breast cancer constituted the most frequent secondary malignan-
cies in concordance with previously published data [32, 33]. Fur-
thermore, BCCs occurred significantly earlier after initial cancer 
diagnosis than meningiomas, which should be considered with re-
gard to risk-adapted surveillance programs [33].
The fact that subsequent neoplasms occurred up to 42 years 
after initial cancer diagnosis emphasizes the need for life-long fol-
low-up including regular examinations and cancer prevention 
measures [34]. Cancer prediction models for certain entities and 
risk groups as well as recommendations for early detection pro-
grams in formerly irradiated patient already exist [12, 35]. How-
ever, most patients in our study group were not aware of their ele-
vated risk for subsequent neoplasms and the need for regular ex-
aminations revealing a relevant lack of information concerning late 
effects in German childhood cancer survivors. 
In our cohort, some patients developed up to 5 additional neo-
plasms after childhood cancer, possibly indicating a genetic cancer 
predisposition. However, although genetic counseling and testing 
constitutes an important part of our multidisciplinary team, no pa-
tient was identified to be affected by a genetic cancer predisposi-
tion. Genetic testing might nonetheless help to identify very high-
risk patients among all irradiated patients for intensive early detec-
tion programs [36].
Above all, study participants were affected by a wide range of 
additional health conditions including cardiac, pulmonary, ortho-
pedic and dermatologic diseases as well as metabolic changes.
There are several limitations to the present study. First, due to 
the study design and the small study size no direct comparison 
with the prevalence of the different chronic health conditions in an 
age- and sex-adjusted general population or in a sibling control co-
hort was performed. Although this complicates the interpretation 
of the study findings, the documented diseases clearly exceed the 
expected prevalence for young adults with a median age of 24 
years. 
Besides, as the application of instrument-based examinations to 
the patients resulted from a risk stratification based on LTFU 
guidelines, some patients with a low risk of developing late effects 
did not receive additional examinations. Thus, the true prevalence 
of chronic health conditions in the study group might be underes-
timated. Furthermore, almost half of the study participants were 
routinely transferred from the local departments of Pediatric He-
matology and Oncology in a transition process and are supposed to 
represent the standard distribution of childhood cancer survivors 
including patients with various primary cancer diagnoses and dif-
ferent risk profiles regarding potential late effects. However, as 
only 17% of all former patients that were contacted via mail and 
invited for long-term follow-up attended the clinics and an addi-
tional share of patients independently decided to visit the clinics 
without medical referral as they found information online, a selec-
tion bias comprising patients with a higher risk profile into the 
study cannot be excluded. The low response rate in the cohort con-
tacted via mail may be due to the fact that no prior address verifica-
tion was performed. Thus, a relevant share of patients that were 
treated in the local departments of Pediatric Hematology and On-
cology several years ago may not have been contacted successfully.
Previous studies already demonstrated an elevated risk for Ger-
man childhood cancer survivors, comparably high to that in Amer-
ican and British Childhood Cancer survivors. However, most stud-
ies assessed therapy sequelae via questionnaire without ascertain-
ing results in a clinical setting or offering specialized care.
This study thus represents to the best of our knowledge the first 
study on German childhood cancer survivors based on clinical ex-
amination. It demonstrates the quantity and complexity of possible 
late effects that have to be considered in a multidisciplinary setting. 
However, the quantitative results require additional confirmatory 
studies in a prospective setting.
Beyond that, the study demonstrates possible structures of com-
prehensive care for this at-risk population. Consequently, a collab-
orating network consisting of several late effects clinics at univer-
sity hospitals in Germany, to establish standardized and risk-
adapted care for long-term childhood cancer survivors, is currently 
under development.
Online Supplemental Table
Supplemental Table 1. Non-malignant chronic health conditions 
(with subcategories).
To access the supplemental table, please refer to www.karger.com/? 
DOI=488203.
Acknowledgements
The study was funded by the ‘Lübeck-Hilfe für krebskranke Kinder e.V.’, 
‘Hand in Hand für Norddeutschland’, ‘Madeleine Schickedanz KinderKrebs-
Stiftung’ and the ‘Förderverein des Tumorzentrums Erlangen’.
Disclosure Statement
The authors declare that the research was conducted in the absence of any 
commercial or financial relationship that could be constructed as a potential 
conflict of interest.
Gebauer/Rieken/Schuster/Hahn/Gebauer/ 
Meidenbauer/Brabant/Metzler/Langer
Oncol Res Treat 2018;41:430–436436
References
 1 Stiller CA, Kroll ME, Pritchard-Jones K: Population 
survival from childhood cancer in Britain during 
1978–2005 by eras of entry to clinical trials. Ann Oncol 
2012; 23: 2464–2469.
 2 Fidler MM, Reulen RC, Winter DL, Kelly J, Jenkinson 
HC, Skinner R, Frobisher C, Hawkins MM, British 
Childhood Cancer Survivor Study Steering G: Long 
term cause specific mortality among 34 489 five year 
survivors of childhood cancer in Great Britain: popula-
tion based cohort study. BMJ 2016; 354:i4351.
 3 Reulen RC, Winter DL, Frobisher C, Lancashire ER, 
Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins 
MM, British Childhood Cancer Survivor Study Steering 
G: Long-term cause-specific mortality among survivors 
of childhood cancer. JAMA 2010; 304: 172–179.
 4 Bowers DC, Nathan PC, Constine L, Woodman C, 
Bhatia S, Keller K, Bashore L: Subsequent neoplasms of 
the CNS among survivors of childhood cancer: a sys-
tematic review. Lancet Oncol 2013; 14:e321–328.
 5 Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, 
Hudson MM, Meadows AT, Friedman DL, Marina N, 
Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisen-
ring W, Robison LL, Childhood Cancer Survivor S: 
Chronic health conditions in adult survivors of child-
hood cancer. N Engl J Med 2006; 355: 1572–1582.
 6 Kam V, Hendershot E, Anderson L, Marjerrison S: 
Evaluation of a joint adult and pediatric clinic for can-
cer survivorship care. Pediatr Blood Cancer 2017; 64: 
e26476.
 7 Hjorth L, Haupt R, Skinner R, Grabow D, Byrne J, 
Karner S, Levitt G, Michel G, van der Pal H, Bardi E, 
Beck JD, de Vathaire F, Essig S, Frey E, Garwicz S, Hawk-
ins M, Jakab Z, Jankovic M, Kazanowska B, Kepak T, 
Kremer L, Lackner H, Sugden E, Terenziani M, Zaletel 
LZ, Kaatsch P, PanCare N: Survivorship after childhood 
cancer: PanCare: a European Network to promote opti-
mal long-term care. Eur J Cancer 2015; 51: 1203–1211.
 8 McClellan W, Fulbright JM, Doolittle GC, Alsman K, 
Klemp JR, Ryan R, Nelson EL, Stegenga K, Krebill H, 
Al-hihi EM, Schuetz N, Heiman A, Lowry B: A Col-
laborative step-wise process to implementing an inno-
vative clinic for adult survivors of childhood cancer. J 
Pediatr Nurs 2015; 30:e147–155.
 9 Denzer C, Brabant G, Brämswig J, Dörffel W, Dörr 
HG, Hauffa BP, Langer T, Müller H, Ott-Renzer C, 
Rohrer T, Schnabel D, Vorwerk P, Wabitsch M: Endo-
krinologische Nachsorge nach onkologischen Erkran-
kungen im Kindes- und Jugendalter, evidenzbasierte 
Leitlinie S3, Version 2014, AWMF-Register Nr. 025-
030. AWMF, 2014, http://www.awmf.org/uploads/ 
tx_szleitlinien/025–030l_S3_Endokrinologische_Nach-
sorge_nach_onkologischen_Erkrankungen_Kindes_Ju-
gendalter_2014_03.pdf .
10 Childrens’ Oncology Group: Long-term follow-up 
guidelines for survivors of childhood, adolescent and 
young adult cancer version 4.0. 2013, http://www.sur-
vivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf.
11 Calaminus G, Dorffel W, Baust K, Teske C, Rie-
penhausen M, Bramswig J, Flechtner HH, Singer S, 
Hinz A, Schellong G: Quality of life in long-term survi-
vors following treatment for Hodgkin’s disease during 
childhood and adolescence in the German multicentre 
studies between 1978 and 2002. Support Care Cancer 
2014; 22: 1519–1529.
12 Schellong G, Riepenhausen M, Ehlert K, Bramswig J, 
Dorffel W, German Working Group on the Long-
Term Sequelae of Hodgkin’s D, Schmutzler RK, Rhiem 
K, Bick U, German Consortium for Hereditary B, 
Ovarian C: Breast cancer in young women after treat-
ment for Hodgkin’s disease during childhood or ado-
lescence – an observational study with up to 33-year 
follow-up. Dtsch Arztebl Int 2014; 111: 3–9.
13 Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier 
W, Levitt G, Constine LS, Wallace WH, van Leeuwen 
FE, Ronckers CM, Henderson TO, Dwyer M, Skinner R, 
Oeffinger KC, International Late Effects of Childhood 
Cancer Guideline Harmonization Group: Recommen-
dations for breast cancer surveillance for female survi-
vors of childhood, adolescent, and young adult cancer 
given chest radiation: a report from the International 
Late Effects of Childhood Cancer Guideline Harmoni-
zation Group. Lancet Oncol 2013; 14:e621–629.
14 Armenian SH, Hudson MM, Mulder RL, Chen MH, 
Constine LS, Dwyer M, Nathan PC, Tissing WJ, 
Shankar S, Sieswerda E, Skinner R, Steinberger J, van 
Dalen EC, van der Pal H, Wallace WH, Levitt G, Kre-
mer LC, International Late Effects of Childhood 
 Cancer Guideline Harmonization Group: Recommen-
dations for cardiomyopathy surveillance for survivors 
of childhood cancer: a report from the International 
Late Effects of Childhood Cancer Guideline Harmoni-
zation Group. Lancet Oncol 2015; 16:e123–136.
15 van Dorp W, Mulder RL, Kremer LC, Hudson MM, 
van den Heuvel-Eibrink MM, van den Berg MH, Lev-
ine JM, van Dulmen-den Broeder E, di Iorgi N, Alba-
nese A, Armenian SH, Bhatia S, Constine LS, Corrias 
A, Deans R, Dirksen U, Gracia CR, Hjorth L, Kroon L, 
Lambalk CB, Landier W, Levitt G, Leiper A, Meacham 
L, Mussa A, Neggers SJ, Oeffinger KC, Revelli A, van 
Santen HM, Skinner R, Toogood A, Wallace WH, 
Haupt R: Recommendations for premature ovarian in-
sufficiency surveillance for female survivors of child-
hood, adolescent, and young adult cancer: a report 
from the International Late Effects of Childhood Can-
cer Guideline Harmonization Group in collaboration 
with the PanCareSurFup Consortium. J Clin Oncol 
2016; 34: 3440–3450.
16 Hudson MM, Ness KK, Gurney JG, Mulrooney DA, 
Chemaitilly W, Krull KR, Green DM, Armstrong GT, 
Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robi-
son LL: Clinical ascertainment of health outcomes 
among adults treated for childhood cancer. JAMA 
2013; 309: 2371–2381.
17 Ducassou S, Chipi M, Pouyade A, Afonso M, Demeaux 
JL, Ducos G, Perel Y, Ansoborlo S: Impact of shared 
care program in follow-up of childhood cancer survi-
vors: An intervention study. Pediatr Blood Cancer 
2017; 64:e26541.
18 Lie HC, Mellblom AV, Brekke M, Finset A, Fossa SD, 
Kiserud CE, Ruud E, Loge JH: Experiences with late 
effects-related care and preferences for long-term fol-
low-up care among adult survivors of childhood lym-
phoma. Support Care Cancer 2017; 25: 2445–2454.
19 Vetsch J, Rueegg CS, Mader L, Bergstraesser E, Diezi 
M, Kuehni CE, Michel G, Swiss Paediatric Oncology 
G: Parents’ preferences for the organisation of long-
term follow-up of childhood cancer survivors. Eur J 
Cancer Care (Engl) 2017; 27:e12649.
20 Sadak KT, Neglia JP, Freyer DR, Harwood E: Identify-
ing metrics of success for transitional care practices in 
childhood cancer survivorship: a qualitative study of 
survivorship providers. Pediatr Blood Cancer 2017
21 Skinner R, Wallace WH, Levitt G: Long-term follow-
up of children treated for cancer: why is it necessary, 
by whom, where and how? Arch Dis Child 2007; 92: 
257–260.
22 Aziz NM, Oeffinger KC, Brooks S, Turoff AJ: Compre-
hensive long-term follow-up programs for pediatric 
cancer survivors. Cancer 2006; 107: 841–848.
23 Mostoufi-Moab S, Seidel K, Leisenring WM, Arm-
strong GT, Oeffinger KC, Stovall M, Meacham LR, 
Green DM, Weathers R, Ginsberg JP, Robison LL, 
Sklar CA: Endocrine abnormalities in aging survivors 
of childhood cancer: a report from the Childhood Can-
cer Survivor Study. J Clin Oncol 2016; 34: 3240–3247.
24 Chemaitilly W, Cohen LE: Diagnosis of endocrine dis-
ease: endocrine late-effects of childhood cancer and its 
treatments. Eur J Endocrinol 2017; 176:R183-203.
25 Garmendia Madariaga A, Santos Palacios S, Guillen-
Grima F, Galofre JC: The incidence and prevalence of 
thyroid dysfunction in Europe: a meta-analysis. J Clin 
Endocrinol Metab 2014; 99: 923–931.
26 Imaizumi M, Usa T, Tominaga T, Neriishi K, Akahoshi 
M, Nakashima E, Ashizawa K, Hida A, Soda M, Fuji-
wara S, Yamada M, Ejima E, Yokoyama N, Okubo M, 
Sugino K, Suzuki G, Maeda R, Nagataki S, Eguchi K: 
Radiation dose-response relationships for thyroid nod-
ules and autoimmune thyroid diseases in Hiroshima 
and Nagasaki atomic bomb survivors 55–58 years after 
radiation exposure. JAMA 2006; 295: 1011–1022.
27 Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, 
Harari A, Haigh PI, Adams AL: Incidence and preva-
lence of primary hyperparathyroidism in a racially 
mixed population. J Clin Endocrinol Metab 2013; 98: 
1122–1129.
28 McMullen T, Bodie G, Gill A, Ihre-Lundgren C, Shun 
A, Bergin M, Stevens G, Delbridge L: Hyperparathy-
roidism after irradiation for childhood malignancy. Int 
J Radiat Oncol Biol Phys 2009; 73: 1164–1168.
29 Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper 
I, Visser JA, Themmen AP, de Jong FH, van den Heu-
vel-Eibrink MM: Assessment of ovarian reserve in 
adult childhood cancer survivors using anti-Mullerian 
hormone. Hum Reprod 2009; 24: 982–990.
30 Chemaitilly W, Li Z, Krasin MJ, Brooke RJ, Wilson CL, 
Green DM, Klosky JL, Barnes N, Clark KL, Farr JB, 
Fernandez-Pineda I, Bishop MW, Metzger M, Pui CH, 
Kaste SC, Ness KK, Srivastava DK, Robison LL, Hud-
son MM, Yasui Y, Sklar CA: Premature ovarian insuf-
ficiency in childhood cancer survivors: a report from 
the St. Jude Lifetime Cohort. J Clin Endocrinol Metab 
2017; 102: 2242-2250.
31 Wang R, Syed IA, Nathan PC, Barr RD, Rosenberg-
Yunger ZR, Klassen AF: Exploring cancer worry in ad-
olescent and young adult survivors of childhood can-
cers. J Adolesc Young Adult Oncol 2015; 4: 192–199.
32 Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, 
Stovall M, Smith SA, Weathers R, Leisenring W, 
Mertens AC, Hammond S, Friedman DL, Neglia JP, 
Meadows AT, Donaldson SS, Sklar CA, Robison LL, 
Inskip PD: Risk of second primary thyroid cancer after 
radiotherapy for a childhood cancer in a large cohort 
study: an update from the childhood cancer survivor 
study. Radiat Res 2010; 174: 741–752.
33 Friedman DL, Whitton J, Leisenring W, Mertens AC, 
Hammond S, Stovall M, Donaldson SS, Meadows AT, 
Robison LL, Neglia JP: Subsequent neoplasms in 
5-year survivors of childhood cancer: the Childhood 
Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 
1083–1095.
34 Ng AK, Travis LB: Subsequent malignant neoplasms in 
cancer survivors. Cancer J 2008; 14: 429–434.
35 Kovalchik SA, Ronckers CM, Veiga LH, Sigurdson AJ, 
Inskip PD, de Vathaire F, Sklar CA, Donaldson SS, An-
derson H, Bhatti P, Hammond S, Leisenring WM, 
Mertens AC, Smith SA, Stovall M, Tucker MA, Weath-
ers RE, Robison LL, Pfeiffer RM: Absolute risk predic-
tion of second primary thyroid cancer among 5-year 
survivors of childhood cancer. J Clin Oncol 2013; 31: 
119–127.
36 Hodgson D, van Leeuwen F, Ng A, Morton L, Hender-
son TO: Breast cancer after childhood, adolescent, and 
young adult cancer: it’s not just about chest radiation. 
Am Soc Clin Oncol Educ Book 2017; 37: 736–745.
